Globus Medical (NYSE:GMED) Director Sells 25,000 Shares of Stock

Globus Medical, Inc. (NYSE:GMED) Director Stephen Zarrilli sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Globus Medical Stock Performance

GMED stock traded up $2.04 during mid-day trading on Wednesday, hitting $88.48. 1,063,950 shares of the company were exchanged, compared to its average volume of 1,496,449. The firm has a market cap of $11.88 billion, a P/E ratio of 22.63, a P/E/G ratio of 1.38 and a beta of 0.95. The firm’s 50 day simple moving average is $80.20 and its 200 day simple moving average is $84.81. Globus Medical, Inc. has a 1-year low of $54.15 and a 1-year high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The firm had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities research analysts predict that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Stifel Nicolaus dropped their price target on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research note on Wednesday, July 8th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. BMO Capital Markets started coverage on Globus Medical in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Monday, July 13th. Finally, Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical currently has a consensus rating of “Moderate Buy” and an average price target of $101.77.

Institutional Investors Weigh In On Globus Medical

A number of institutional investors and hedge funds have recently made changes to their positions in GMED. Northwestern Mutual Wealth Management Co. grew its stake in shares of Globus Medical by 71,618.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company’s stock valued at $62,555,000 after buying an additional 715,470 shares in the last quarter. WCM Investment Management LLC bought a new position in Globus Medical during the first quarter worth about $16,965,000. SG Americas Securities LLC increased its position in Globus Medical by 241.1% during the first quarter. SG Americas Securities LLC now owns 340,452 shares of the medical device company’s stock worth $29,333,000 after buying an additional 240,642 shares during the last quarter. Artemis Investment Management LLP raised its stake in Globus Medical by 43.7% in the fourth quarter. Artemis Investment Management LLP now owns 738,595 shares of the medical device company’s stock valued at $64,487,000 after buying an additional 224,587 shares during the period. Finally, Hyperion Capital Advisors LP bought a new position in shares of Globus Medical during the 4th quarter worth approximately $12,822,000. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.